Quarterly ResultAug 13, 2026, 04:25 PM
Eton Pharma Q2 Revenue +98.6% to $37.59M; Net Income $11.58M
AI Summary
Eton Pharmaceuticals reported strong financial results for Q2 2026, with net revenues nearly doubling to $37.59 million and a significant turnaround to a net income of $11.58 million, or $0.35 diluted EPS, compared to a net loss in the prior year. For the first six months of 2026, net revenues increased by 70.8% to $61.86 million, resulting in a net income of $13.13 million. The company also saw an increase in total assets to $115.81 million, driven partly by investments in product license rights.
Key Highlights
- Q2 2026 net revenues increased 98.6% to $37.59 million.
- Q2 2026 net income was $11.58 million, up from a $2.59 million net loss.
- Diluted EPS for Q2 2026 was $0.35, compared to $(0.10) in Q2 2025.
- Six-month 2026 net revenues rose 70.8% to $61.86 million.
- Six-month 2026 net income was $13.13 million, reversing a $4.16 million net loss.
- Net cash from operating activities for six months was $14.66 million.
- Total assets increased to $115.81 million as of June 30, 2026.
- Intangible assets grew to $45.68 million, including $15 million in new license rights.
Price Impact
More from ETON